Cargando…

The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients

BACKGROUND: Mucopolysaccharidosis type II (MPS II) or Hunter syndrome is an X-linked recessive lysosomal storage disorder resulting from deficient activity of iduronate 2-sulfatase (IDS) and the progressive lysosomal accumulation of sulfated glycosaminoglycans (GAGs). METHODS: A diagnosis of MPS II...

Descripción completa

Detalles Bibliográficos
Autores principales: Chkioua, L, Grissa, O, Leban, N, Gribaa, M, Boudabous, H, Turkia, H Ben, Ferchichi, S, Tebib, N, Laradi, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247178/
https://www.ncbi.nlm.nih.gov/pubmed/32448126
http://dx.doi.org/10.1186/s12881-020-01051-9
_version_ 1783538105389678592
author Chkioua, L
Grissa, O
Leban, N
Gribaa, M
Boudabous, H
Turkia, H Ben
Ferchichi, S
Tebib, N
Laradi, S
author_facet Chkioua, L
Grissa, O
Leban, N
Gribaa, M
Boudabous, H
Turkia, H Ben
Ferchichi, S
Tebib, N
Laradi, S
author_sort Chkioua, L
collection PubMed
description BACKGROUND: Mucopolysaccharidosis type II (MPS II) or Hunter syndrome is an X-linked recessive lysosomal storage disorder resulting from deficient activity of iduronate 2-sulfatase (IDS) and the progressive lysosomal accumulation of sulfated glycosaminoglycans (GAGs). METHODS: A diagnosis of MPS II or Hunter syndrome was performed based on the following approach after a clinical and paraclinical suspicion. Two biochemical and molecular tests were carried out separately and according to the availability of the biological material. RESULTS: All patients in this cohort presented the most common MPS II clinical features. Electrophoresis of GAGs on a cellulose acetate plate in the presence of a high concentration of heparane sulfate showed an abnormal dermatan sulfate band in the patients compared with that in a control case. Furthermore, leukocyte IDS activity ranged from 0.00 to 0.75 nmol/h/mg of leukocyte protein in patients. Five previously reported mutations were identified in this study patients: one splice site mutation, c.240 + 1G > A; two missense mutations, p.R88P and p.G94D; a large deletion of exon 1 to exon 7; and one nonsense mutation, p.Q396*. In addition, two novel alterations were identified in the MPS II patients: one frame shift mutation, p.D450Nfs*95 and one nonsense mutation, p.Q204*. Additionally, five known IDS polymorphisms were identified in the patients: c.419–16 delT, c.641C > T (p.T214M), c.438 C > T (p.T146T), c.709-87G > A, and c.1006 + 38 T > C. CONCLUSIONS: The high level of urine GAGs and the deficiency of iduronate 2-sulfatase activity was associated with the phenotype expression of Hunter syndrome. Molecular testing was useful for the patients’ phenotypic classification and the detection of carriers.
format Online
Article
Text
id pubmed-7247178
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72471782020-06-01 The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients Chkioua, L Grissa, O Leban, N Gribaa, M Boudabous, H Turkia, H Ben Ferchichi, S Tebib, N Laradi, S BMC Med Genet Research Article BACKGROUND: Mucopolysaccharidosis type II (MPS II) or Hunter syndrome is an X-linked recessive lysosomal storage disorder resulting from deficient activity of iduronate 2-sulfatase (IDS) and the progressive lysosomal accumulation of sulfated glycosaminoglycans (GAGs). METHODS: A diagnosis of MPS II or Hunter syndrome was performed based on the following approach after a clinical and paraclinical suspicion. Two biochemical and molecular tests were carried out separately and according to the availability of the biological material. RESULTS: All patients in this cohort presented the most common MPS II clinical features. Electrophoresis of GAGs on a cellulose acetate plate in the presence of a high concentration of heparane sulfate showed an abnormal dermatan sulfate band in the patients compared with that in a control case. Furthermore, leukocyte IDS activity ranged from 0.00 to 0.75 nmol/h/mg of leukocyte protein in patients. Five previously reported mutations were identified in this study patients: one splice site mutation, c.240 + 1G > A; two missense mutations, p.R88P and p.G94D; a large deletion of exon 1 to exon 7; and one nonsense mutation, p.Q396*. In addition, two novel alterations were identified in the MPS II patients: one frame shift mutation, p.D450Nfs*95 and one nonsense mutation, p.Q204*. Additionally, five known IDS polymorphisms were identified in the patients: c.419–16 delT, c.641C > T (p.T214M), c.438 C > T (p.T146T), c.709-87G > A, and c.1006 + 38 T > C. CONCLUSIONS: The high level of urine GAGs and the deficiency of iduronate 2-sulfatase activity was associated with the phenotype expression of Hunter syndrome. Molecular testing was useful for the patients’ phenotypic classification and the detection of carriers. BioMed Central 2020-05-24 /pmc/articles/PMC7247178/ /pubmed/32448126 http://dx.doi.org/10.1186/s12881-020-01051-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Chkioua, L
Grissa, O
Leban, N
Gribaa, M
Boudabous, H
Turkia, H Ben
Ferchichi, S
Tebib, N
Laradi, S
The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients
title The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients
title_full The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients
title_fullStr The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients
title_full_unstemmed The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients
title_short The mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in Tunisian patients
title_sort mutational spectrum of hunter syndrome reveals correlation between biochemical and clinical profiles in tunisian patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247178/
https://www.ncbi.nlm.nih.gov/pubmed/32448126
http://dx.doi.org/10.1186/s12881-020-01051-9
work_keys_str_mv AT chkioual themutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT grissao themutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT lebann themutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT gribaam themutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT boudaboush themutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT turkiahben themutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT ferchichis themutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT tebibn themutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT laradis themutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT chkioual mutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT grissao mutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT lebann mutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT gribaam mutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT boudaboush mutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT turkiahben mutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT ferchichis mutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT tebibn mutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients
AT laradis mutationalspectrumofhuntersyndromerevealscorrelationbetweenbiochemicalandclinicalprofilesintunisianpatients